May 14, 2020 / 01:40PM GMT
Yang Huang - BofA Merrill Lynch, Research Division - Research Analyst
Hello, everyone. Thank you for coming and to join the call for I-Mab. I'm Bank of America analyst, Yang Huang, covering China health care. And today, we're inviting Dr. Zang Jingwu to give our -- a presentation to introduce the most recent update for I-Mab. As you know, I-Mab recently IPO-ed and has quite a few updates on its clinical pipeline.
And yes, so Dr. Zang, you can start.
Jingwu Zhang Zang - I-Mab - Founder, Honorary Chairman & Director
Pleased to introduce I-Mab biopharma. I-Mab biopharma is unique among China-based biotech companies as we only focus on discovery, development and the future commercialization of biologics, innovative biologics with first-in-class, best-in-class potential. This focus is mostly attributable to our R&D strengths in immunology, and we stand out as a leading immunology company in China.
If you turn to Page 2, we have been taking 2 strategies to build our pipeline. One strategy, I'll call it, global strategy, where we rely on
I-Mab at Bank of America Merrill Lynch Healthcare Conference (Virtual) Transcript
Feb 29, 2024
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers